Silmitasertib Granted Orphan Drug Status for Medulloblastoma
The FDA has granted Orphan Drug designation to silmitasertib for the treatment of patients with medulloblastoma.
Source: empr.com
John Soong News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from John Soong. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In John Soong Today - Breaking & Trending Today
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...
Source: prnewswire.com
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...
Source: prnewswire.com
Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics...
Source: prnewswire.com
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
Share this article Share this article TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investigator-initiated trial (IIT) of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in Phoenix, Arizona (BUMCP). This IIT is a Phase II multi-center, open-label, randomized, control...
Source: prnewswire.com